Peter Radovich Sells 4,303 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 4,303 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the sale, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Monday, January 8th, Peter Radovich sold 1,408 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $28.03, for a total transaction of $39,466.24.

Mirum Pharmaceuticals Trading Up 0.8 %

Shares of MIRM opened at $25.12 on Thursday. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23. Mirum Pharmaceuticals, Inc. has a twelve month low of $21.83 and a twelve month high of $35.56. The firm’s 50 day moving average price is $27.49 and its two-hundred day moving average price is $29.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The company had revenue of $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Silverarc Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 0.4% during the second quarter. Silverarc Capital Management LLC now owns 106,375 shares of the company’s stock worth $2,752,000 after purchasing an additional 436 shares during the last quarter. Metropolitan Life Insurance Co NY boosted its holdings in Mirum Pharmaceuticals by 49.7% during the second quarter. Metropolitan Life Insurance Co NY now owns 1,464 shares of the company’s stock worth $38,000 after purchasing an additional 486 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Mirum Pharmaceuticals by 98.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after purchasing an additional 488 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 1.2% during the third quarter. Los Angeles Capital Management LLC now owns 42,444 shares of the company’s stock worth $1,341,000 after purchasing an additional 494 shares during the last quarter. Finally, Royal Bank of Canada raised its position in Mirum Pharmaceuticals by 40.1% during the second quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock worth $48,000 after acquiring an additional 530 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $45.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. SVB Leerink reduced their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, March 14th. Finally, Raymond James reduced their price objective on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 19th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $52.11.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.